UN008

UN008 is an ultra-long-acting **glucagon-like peptide-1 (GLP-1) receptor agonist** developed by Guangzhou Youhuikang Biotechnology Co., Ltd. It is designed to mimic the action of the endogenous GLP-1 hormone, which plays a critical role in glucose homeostasis by stimulating insulin secretion, inhibiting glucagon release, and slowing gastric emptying. The drug utilizes a proprietary technology platform intended to significantly extend its half-life, potentially offering a superior dosing schedule compared to existing GLP-1 therapies. UN008 is primarily being developed for the treatment of metabolic disorders, including **type 2 diabetes** and **obesity**. It is currently undergoing Phase 1 clinical evaluation in healthy volunteers to assess its safety, tolerability, and pharmacokinetic profile.